Health Care • Biotechnology: Pharmaceutical Preparations
$20.76 ▼ -0.31
(-1.47%)
MKT CAP: $2.48B • VOL: 1.03M
52W L $19 52W H $42
NAMS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $22.5M | $45.6M | $14.1M |
| YoY Revenue Growth % | -50.6% | +223.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$225.7M | -$176.3M | -$183.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$203.0M | -$242.0M | -$177.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$147.8M | -$158.6M | -$141.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$147.8M | -$158.6M | -$141.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $490.0M | $771.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $683.4M | $757.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NAMS.